37,595 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL bought a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 37,595 shares of the company’s stock, valued at approximately $1,023,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its position in shares of IDEAYA Biosciences by 1.5% in the 3rd quarter. Arizona State Retirement System now owns 23,324 shares of the company’s stock worth $635,000 after purchasing an additional 353 shares during the period. Daiwa Securities Group Inc. increased its position in shares of IDEAYA Biosciences by 16.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after buying an additional 436 shares during the period. PNC Financial Services Group Inc. raised its stake in IDEAYA Biosciences by 16.1% during the third quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock worth $106,000 after buying an additional 537 shares during the last quarter. E Fund Management Co. Ltd. raised its stake in IDEAYA Biosciences by 7.8% during the second quarter. E Fund Management Co. Ltd. now owns 12,225 shares of the company’s stock worth $257,000 after buying an additional 881 shares during the last quarter. Finally, Sio Capital Management LLC lifted its holdings in IDEAYA Biosciences by 1.0% in the second quarter. Sio Capital Management LLC now owns 124,230 shares of the company’s stock valued at $2,611,000 after buying an additional 1,230 shares during the period. Institutional investors own 98.29% of the company’s stock.

Insider Transactions at IDEAYA Biosciences

In other news, Director Jeffrey Stein acquired 50,000 shares of IDEAYA Biosciences stock in a transaction on Monday, March 2nd. The stock was purchased at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the purchase, the director owned 54,281 shares of the company’s stock, valued at approximately $1,789,101.76. The trade was a 1,167.95% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.50% of the company’s stock.

IDEAYA Biosciences Trading Up 3.3%

Shares of NASDAQ IDYA opened at $31.45 on Tuesday. The firm has a market capitalization of $2.76 billion, a P/E ratio of -24.01 and a beta of 0.09. The firm’s 50-day moving average price is $32.91 and its 200-day moving average price is $32.11. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.09. The firm had revenue of $21.75 million during the quarter, compared to analyst estimates of $5.95 million. During the same quarter in the prior year, the business earned ($1.49) earnings per share. The business’s quarterly revenue was up 55.7% on a year-over-year basis. Equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on IDYA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Thursday, January 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a research note on Wednesday, February 18th. Wedbush upped their target price on IDEAYA Biosciences from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Guggenheim reiterated a “buy” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Finally, UBS Group initiated coverage on IDEAYA Biosciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price for the company. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.69.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.